细胞免疫治疗基因测序后的下一个万亿市场（Cellular immunotherapy the next trillion markets after gene sequencing）.docVIP

下载本文档

4
0
约1.1万字
约 8页
2017-09-02 发布于河南
举报
版权申诉

细胞免疫治疗基因测序后的下一个万亿市场（Cellular immunotherapy the next trillion markets after gene sequencing）.doc

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

细胞免疫治疗基因测序后的下一个万亿市场（Cellular immunotherapy the next trillion markets after gene sequencing）

细胞免疫治疗基因测序后的下一个万亿市场（Cellular immunotherapy the next trillion markets after gene sequencing） Cellular immunotherapy: the next trillion markets after gene sequencing A fuse, speculation originates from a report on the former UBS Securities UBS Securities recently issued a research report that is expected to become the field of tumor immunotherapy products under a gold mine. The clinical results show that tumor immunotherapy has a good prospect of application: the use of the bodys own immune system to treat tumors, that is, tumor immunotherapy, has become the focus of research and development of international pharmaceutical companies. Tumor immunotherapy mainly includes nonspecific immune stimulation, immunological test point, monoclonal antibody, adoptive T cell therapy, tumor vaccine and so on. Immunotherapy for cancer is expected to treat more than 60% of tumor types and is expected to lead to market opportunities of over $25 billion, or the next gold mine in the field of cancer therapy. UBS Securities believes that the adoptive T cell therapy (ACT therapy) is a kind of tumor immunotherapy, current clinical experimental results show its incomparable advantages: to cure patients with advanced melanoma patients, but is not only prolong the survival period. In ACT therapy, chimeric antigen receptor modified T cell therapy (CAR) is the most promising because of its better specificity. Novartiss CART-19 has completed phase 2 clinical trials. According to the research report, the market size of CART-19 products could reach 80-100 us dollars. (note that this is only one of the companys products have reached the market scale of RMB billions, is not the whole industry market valuation) In China, cell immunotherapy is still under the name of third types of medical technology. There are about 3 million 70 thousand new cancer cases diagnosed each year in our country, and the potential market for cell therapy is vast. However, due to the absence of supervision, there is a little